• banner1
  • banner2
  • banner3
  • wowslideshow
  • banner5
banner11 banner22 banner33 banner44 banner55

News & Events

Labmate Partners with EpiCypher

EpiCypher has pioneered the manufacture of nucleosomes for epigenetics research and drug discovery, producing the highest quality products available which include fully defined and homogeneous recombinant nucleosomes incorporating different DNA and histone modifications, site mutations, or histone variants.

Labmate Partners with GenomeMe

GenomeMe develops immunohistochemistry (IHC) antibodies targeting the critical markers you need to make your diagnosis with confidence.

Are you looking for Micro volume Spectrophotometer from Berthold

Labmate Partners with Horizon Discovery!!

Horizon Discovery provides rAAV, ZFN and CRISPR custom and off the shelf cell lines and in vivo model for research and bioproduction applications, quantitative molecular reference standards, in vivo disease models, contract research and custom screening services for target identification and validation, and for drug combination studies.

  Cell Screening
Read More Downloads Contact Us

Selection of High Yielding Mammalian Clones

Model : Clonepix 2 from Molecular Devices, USA

Introduction:ClonePix FL is an unique stand-alone system which uses proprietary technology to selectively identify isolate and develop only the most valuable cell lines.

ClonePix FL is a paradigm shift in technology that uses fluorescence imaging to identify and quantify colonies expressing or secreting non-labelled proteins combined with high accuracy picking of mammalian cells in culture.

With the traditional method namely limiting dilution – selection is done only using white light imaging, but with respect to ClonePix FL (patented technology) selection is done using Fluorescence imaging. Hence it is impossible to select the high secretors using white light imaging as shown in the above to images.

ClonePix FL enables the user to screen thousands of clones at a time and eliminate 95 to 98% of all non productive clones in days rather than months. In addition the ability to screen clone for instability and monoclonality in days rather than months make this system far superior to limiting dilutions.

Today over 120 leading Pharma and Biotech companies have invested in this technology to remove un-necessary cost and time to process their projects and take forward their clones to commercial drug development.